NTHI NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

Date	Price Target	Rating	Analyst

See more ratings

NeOnc Technologies Holdings Inc. Press Releases

Fastest customizable press release news feed in the world

View All

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group — a global health company powered by Artificial Intelligence (AI), technology and genomics. In a con

10/9/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), the closing of the previously announced $50 million strategic partnership is mandated to occur no later than October 23rd, 2025, as stipulated by the definitive signed agreement. The finalization of these administrative requirements in the UAE official

10/6/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

10/2/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P

10/1/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. "We are incredibly ho

9/29/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT

CALABASAS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, will be featured on Health Uncensored hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Lifetime Network, available to approximately 63 million television households in the United States, on September 25th, premiering nationwide at 8:00 a.m. ET/PT. The show averages over 500,000 viewers per episode, underscoring the significant national exposure of this feature. Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies, and Dr. Thomas Chen, CE

9/22/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (NASDAQ:BGL) ("Blue Gold" or the "Company"), a next-generation gold development and technology company, today announced the appointment of Sameer Salgar, Founding Partner and Chief Financial Officer of Quazar Investment, to its Advisory Board. Sameer brings over 20 years of investment, corporate finance, and strategic advisory experience. As co-founder of Quazar Investment, a UAE-based private investment firm, he has built a reputation for leading transformational cross-border transactions and connecting growth companies with global capital partners. His addition to the Advisory Board underscores Blue Gold's commitment to scal

9/10/25 9:40:00 AM ET

$BGL

$NTHI

Metal Mining

Basic Materials

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. The FDA's decision follows the successful completion of the Phase I dose-escalation study, which demonstrated that NEO212 could be safely administered at doses up to 810 mg daily on Days 1–5 of a 28-day cycle. Independent review of the recommended Phase II dose is ongoing, with patient enrol

9/10/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc's drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers. The newly acquired IP, which includes U.S. Patent No. 11,788,057 B2, allows NeOnc to create highly sophisticated, patient-derived 3D brain tumor model

8/25/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Second Quarter & Recent Corporate Highlights $50 Million Strategic Partnership Secured – All contingencies finalized with Quazar Investment following incorporation of NuroMENA Holdings under Abu Dhabi Global Market (ADGM). This partnership will launch an advanced GCC & MENA clini

8/19/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings Inc. Leadership Updates

Live Leadership Updates

View All

NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

10/2/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

10/1/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

9/29/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

9/10/25 9:40:00 AM ET

$BGL

$NTHI

Metal Mining

Basic Materials

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features cutting-edge 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug dis

7/30/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational

6/6/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. Press Releases

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals

NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on "Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

NeOnc Technologies Holdings Inc. Insider Purchases

President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

CFO Garnett Keithly bought $4,921 worth of shares (675 units at $7.29), increasing direct ownership by 0.28% to 240,900 units (SEC Form 4)

CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

CFO Garnett Keithly decreased direct ownership by 0.03% to 330,000 units (SEC Form 4)

CEO Chen Thomas C bought $2,800 worth of shares (400 units at $7.00), increasing direct ownership by 0.07% to 546,200 units (SEC Form 4)

President Heshmatpour Amir F bought $47,294 worth of shares (6,490 units at $7.29) and bought $59,221 worth of CommonStock (3,510 units at $16.87), increasing direct ownership by 0.57% to 1,760,000 units (SEC Form 4)

NeOnc Technologies Holdings Inc. Leadership Updates

NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Holdings Inc. SEC Filings

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

SEC Form 8-K filed by NeOnc Technologies Holdings Inc.

SEC Form NT 10-Q filed by NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. Insider Trading

SEC Form 3 filed by new insider Puri Ishwar Kanwar

Chief Clinical Officer Neman-Ebrahim Yousha was granted 133,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Neman-Ebrahim Yousha

Amendment: Director Chiang Ming-Fu (Alan) was granted 50,000 shares, disposed of 5,994 shares, exercised 117,188 in-the-money shares at a strike of $12.00 and sold $1,433,912 worth of shares (57,696 units at $24.85), increasing direct ownership by 15% to 390,216 units (SEC Form 4)

Amendment: COO Walters Patrick disposed of 1,231 shares, exercised 24,063 in-the-money shares at a strike of $12.00 and sold $294,432 worth of shares (11,847 units at $24.85) (SEC Form 4)

Amendment: CFO Garnett Keithly disposed of 687 shares, exercised 13,438 in-the-money shares at a strike of $12.00 and sold $164,426 worth of shares (6,616 units at $24.85) (SEC Form 4)

Amendment: Director Heshmatpour Amir F disposed of 3,996 shares, exercised 78,125 in-the-money shares at a strike of $12.00 and sold $955,941 worth of shares (38,464 units at $24.85) (SEC Form 4)

Amendment: CEO Chen Thomas C disposed of 4,076 shares, exercised 79,688 in-the-money shares at a strike of $12.00 and sold $975,055 worth of shares (39,233 units at $24.85) (SEC Form 4)

President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)